Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a ...

for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy. Previously, penpulimab was approved for use as a third-line treatment for ...

Throat cancer occurs due to the body's uncontrolled growth of abnormal cells within one of the three parts of the throat: the nasopharynx ... but early detection and treatment can significantly ...

Deborah Wong, MD, PhD, discusses the toripalimab combination that is now considered standard of care in nasopharyngeal cancer ...

Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal ... Innovation, and Cancer Innovative Research Program ...

Discover the latest advancements, key Nasopharyngeal Cancer Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Chinese scientists have developed a new treatment for nasopharyngeal ... that often cause severe side effects. Nasopharyngeal carcinoma is a type of cancer that originates in the nasopharynx ...

HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the ...